The Filing Desk

Mangoceuticals vs Exagen

Mangoceuticals MGRX · Exagen XGN · Health Care Services

Exagen reported revenue of $67 million in fiscal 2025, 133.2 times Mangoceuticals' $0 million in fiscal 2025. Mangoceuticals' revenue fell 26.0% in its latest year, and Exagen's grew 19.6%. Mangoceuticals had an operating margin of -3954.3%, against -21.1% at Exagen.

Side by side

MangoceuticalsExagen
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$67M
Revenue growth−26.0%19.6%
Revenue growth a year, last 5 years—9.7%
Gross margin54.9%58.3%
Operating margin−3,954.3%−21.1%
Net margin−4,526.8%−30.0%
Free cash flow—−$14M
Free cash flow margin—−21.4%
Return on capital—−115.0%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count408.9%18.4%
Last close$0.13$3.80
P/E at the last close——
Insider trades, last 12 months—sold $252,640
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MangoceuticalsExagen
Operating margin
Percent of revenue
MangoceuticalsExagen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MangoceuticalsExagen

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Mangoceuticals and Exagen pages.